Acute Occupancy of Brain Serotonin Transporter by Sertraline as Measured by [11C]DASB and Positron Emission Tomography
暂无分享,去创建一个
Ramin V. Parsey | Justine M. Kent | Victoria Arango | Maria A. Oquendo | V. Arango | R. Parsey | T. Cooper | J. Mann | M. Oquendo | J. Mann | T. Cooper | J. Kent | M. Richards | J. John Mann | Thomas B. Cooper | Misty C. Richards | Mali Pratap | M. Pratap | M. Oquendo
[1] J. Mendels,et al. Sertraline safety and efficacy in major depression: A double-blind fixed-dose comparison with placebo , 1995, Biological Psychiatry.
[2] R. Blakely,et al. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. , 1997, European journal of pharmacology.
[3] N. Volkow,et al. Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[4] M. Torrens. Co-Planar Stereotaxic Atlas of the Human Brain—3-Dimensional Proportional System: An Approach to Cerebral Imaging, J. Talairach, P. Tournoux. Georg Thieme Verlag, New York (1988), 122 pp., 130 figs. DM 268 , 1990 .
[5] Alan A. Wilson,et al. Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. , 2001, The American journal of psychiatry.
[6] Mark Slifstein,et al. Comparative evaluation of serotonin transporter radioligands 11C-DASB and 11C-McN 5652 in healthy humans. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[7] R. V. Van Heertum,et al. Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with [11C]McN 5652 , 2002, Psychopharmacology.
[8] E. Cabanis,et al. The Human Brain: Surface, Three-Dimensional Sectional Anatomy and Mri , 1991 .
[9] R Todd Ogden,et al. Estimation of kinetic parameters in graphical analysis of PET imaging data , 2003, Statistics in medicine.
[10] Sylvain Houle,et al. In vitro and in vivo characterisation of [11C]-DASB: a probe for in vivo measurements of the serotonin transporter by positron emission tomography. , 2002, Nuclear medicine and biology.
[11] T. Cooper,et al. Sensitive and selective liquid-chromatographic assay of fluoxetine and norfluoxetine in plasma with fluorescence detection after precolumn derivatization. , 1992, Clinical chemistry.
[12] J. Cummings,et al. The neuroanatomy of depression. , 1993, The Journal of clinical psychiatry.
[13] A. Bystritsky,et al. Placebo-controlled, multicenter study of sertraline treatment for obsessive-compulsive disorder. , 1999, Journal of clinical psychopharmacology.
[14] Alan A. Wilson,et al. Positron Emission Tomography Quantification of [11C]-DASB Binding to the Human Serotonin Transporter: Modeling Strategies , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[15] M Slifstein,et al. In vivo quantification of brain serotonin transporters in humans using [11C]McN 5652. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[16] Stephen M. Smith,et al. A global optimisation method for robust affine registration of brain images , 2001, Medical Image Anal..
[17] S. Houle,et al. Novel Radiotracers for Imaging the Serotonin Transporter by Positron Emission Tomography: Synthesis, Radiosynthesis, and in Vitro and ex Vivo Evaluation of (11)C-Labeled 2-(Phenylthio)araalkylamines. , 2000, Journal of medicinal chemistry.
[18] Yoshiro Okubo,et al. High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. , 2003, Archives of general psychiatry.
[19] M Slifstein,et al. Effects of statistical noise on graphic analysis of PET neuroreceptor studies. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[20] Allan L. Reiss,et al. Reliability and validity of MRI measurement of the amygdala and hippocampus in children with fragile X syndrome , 1997, Psychiatry Research: Neuroimaging.
[21] S. Preskorn,et al. Sertraline 50 mg daily: the optimal dose in the treatment of depression. , 1995, International clinical psychopharmacology.
[22] J. John Mann,et al. Localized alterations in pre- and postsynaptic serotonin binding sites in the ventrolateral prefrontal cortex of suicide victims , 1995, Brain Research.
[23] J. Guelfi,et al. Treatment of dysthymia with sertraline: a double-blind, placebo-controlled trial in dysthymic patients without major depression. , 2000, The Journal of clinical psychiatry.
[24] T Sandor,et al. An interactive procedure for extracting features of the brain from magnetic resonance images: The lobes , 1997, Human brain mapping.
[25] Alan A. Wilson,et al. Imaging the serotonin transporter with positron emission tomography: initial human studies with [11C]DAPP and [11C]DASB , 2000, European Journal of Nuclear Medicine.
[26] M. Mintun,et al. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.
[27] Sylvain Houle,et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. , 2004, The American journal of psychiatry.
[28] M. First,et al. Structured clinical interview for DSM-IV axis I disorders : SCID-I : clinical version : scoresheet , 1997 .
[29] John Hilton,et al. Comparison of (+)-11C-McN5652 and 11C-DASB as Serotonin Transporter Radioligands Under Various Experimental Conditions , 2002 .
[30] C. Montigny,et al. Serotonin and Drug-Induced Therapeutic Responses in Major Depression, Obsessive–Compulsive and Panic Disorders , 1999, Neuropsychopharmacology.
[31] L. Goodman,et al. The Pharmacological Basis of Therapeutics , 1941 .
[32] Ramin V. Parsey,et al. Determination of Volume of Distribution using Likelihood Estimation in Graphical Analysis: Elimination of Estimation Bias , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[33] Alexander Hammers,et al. Automatic segmentation of the brain and intracranial cerebrospinal fluid in T1‐weighted volume MRI scans of the head, and its application to serial cerebral and intracranial volumetry , 2003, Magnetic resonance in medicine.
[34] Robert B. Innis,et al. SPECT Quantification of [123I]Iomazenil Binding to Benzodiazepine Receptors in Nonhuman Primates: II. Equilibrium Analysis of Constant Infusion Experiments and Correlation with in vitro Parameters , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[35] M. Dı́az-Marsá,et al. Sertraline in the treatment of mixed anxiety and depression disorder. , 1997, Journal of affective disorders.
[36] R. Shelton. The dual-action hypothesis: does pharmacology matter? , 2004, The Journal of clinical psychiatry.
[37] Osama Mawlawi,et al. Imaging Human Mesolimbic Dopamine Transmission with Positron Emission Tomography: I. Accuracy and Precision of D2 Receptor Parameter Measurements in Ventral Striatum , 2001, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[38] John Hilton,et al. as Serotonin Transporter Radioligands Under Various Experimental Conditions , 2002 .
[39] A. Carlsson,et al. Nicotine treatment of obsessive–compulsive disorder , 2004, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[40] P. Brust,et al. Autoradiographic imaging of the serotonin transporter in the brain of rats and pigs using S-([18F]fluoromethyl)-(+)-McN5652 , 2003, European Neuropsychopharmacology.
[41] U. Albert,et al. Sertraline treatment of obsessive-compulsive disorder: efficacy and tolerability of a rapid titration regimen , 2002, European Neuropsychopharmacology.
[42] M Slifstein,et al. Validation and Reproducibility of Measurement of 5-HT1A Receptor Parameters with [carbonyl-11C]WAY-100635 in Humans: Comparison of Arterial and Reference Tissue Input Functions , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[43] A Frazer,et al. Effects of Chronic Antidepressant Treatments on Serotonin Transporter Function, Density, and mRNA Level , 1999, The Journal of Neuroscience.
[44] Christer Halldin,et al. PET Studies of Binding Competition between Endogenous Dopamine and the D1 Radiotracer [11C]NNC 756 , 1998, NeuroImage.
[45] Jeih-San Liow,et al. Linearized Reference Tissue Parametric Imaging Methods: Application to [11C]DASB Positron Emission Tomography Studies of the Serotonin Transporter in Human Brain , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[46] Marie-José Bélanger,et al. Biodistribution and radiation dosimetry of [11C]DASB in baboons. , 2004, Nuclear medicine and biology.
[47] Sylvain Houle,et al. Regional distribution of serotonin transporter protein in postmortem human brain: is the cerebellum a SERT-free brain region? , 2005, Nuclear medicine and biology.
[48] H. Duvernoy. The Human Brain , 1999, Springer Vienna.